Nutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins

Reuters

04-29

<a href="https://laohu8.com/S/NTRB">Nutriband Inc.</a> Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins

Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P Therapeutics LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-036201), on April 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2531790264"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531790264\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531790264?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531790264","market":"us","top_or_hot":-1,"title":"Nutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NTRB\">Nutriband Inc.</a> Reports Stable Sales with No Revenue from R&amp;D Services; Gross Margin Declines Due to Lower Tape Sales Margins\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-036201), on April 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-04-29 05:22</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/NTRB\">Nutriband Inc.</a> Reports Stable Sales with No Revenue from R&amp;D Services; Gross Margin Declines Due to Lower Tape Sales Margins\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-036201), on April 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRB","symbol_name":"Nutriband Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nNDL3K8PXS:1","article_id":"2531790264","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531790264","pubTimestamp":1745875333,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P Therapeutics LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NTRB":"Nutriband Inc."},"translate_title":"Nutriband Inc.报告销售额稳定，没有研发服务收入；由于胶带销售利润率下降，毛利率下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRB":0.9},"content_text":"Nutriband Inc. Reports Stable Sales with No Revenue from R&D Services; Gross Margin Declines Due to Lower Tape Sales Margins\n    \n\n        Nutriband Inc. has released its annual report for the fiscal year ending January 31, 2025. The company reported proceeds of $8.4 million from equity financing with European investors on April 19, 2024. Management has expressed confidence in generating sufficient funds from operations to support the company's activities for the next twelve months, indicating improved business performance and the ability to continue as a going concern. In a significant business update, Nutriband's primary focus remains on the development of its AVERSA™ Abuse Deterrent Transdermal Products. The consolidated financial statements include the operations of its wholly owned subsidiaries, Nutriband Ltd., 4P Therapeutics LLC, and Pocono Pharmaceuticals Inc. The company continues to evaluate its estimates and assumptions to ensure accurate financial reporting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-036201), on April 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}